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Comparison of SVS and ESVS Carotid Disease
Management Guidelines*C. Liapis*, W.C. Mackey, B. Perler, P. CaoTufts Medical Center, 800 Washington Street, Box 1035, 02111 Boston, MA, USABoth the Society for Vascular Surgery (SVS) and the Euro-
pean Society for Vascular Surgery (ESVS) have now pub-
lished clinical practice guidelines for the management of
carotid artery atherosclerosis.1,2 While the documents
differ slightly in the methods employed and in the level of
detail, they reveal transatlantic consensus in most key
areas. The SVS document employs the GRADE system which
rates strength of recommendations (IZ Strong and IIZweak)
separately from the quality of the data on which these
recommendations are based (High, Moderate, Low, Very
Low). In this system recommendations are based not just on
data but on prevailing values and preferences3. The ESVS
document employs a simpler system in which only the
quality of the supporting data are graded (A: supported by
at least one high quality randomized controlled trial (RCT),
B: supported by good clinical trials but no RCTs, and C:
supported only by expert opinion or experience). Despite
this fundamental methodological difference, the guidelines
that emerge are quite similar (Table 1).
First, in symptomatic patients there is a consensus that
carotid endarterectomy (CEA) is most appropriate for
patients with carotid territory TIA or minor stroke with
good recovery and 50% or greater (NASCET criteria) ipsi-
lateral stenosis (SVS: Grade 1/High, ESVS: A). The ESVS adds
a guideline that CEA in symptomatic patients should take
place within two weeks of the symptom, based on an* This paper is published simultaneously in European Journal
of Endovascular Surgery and Journal of Vascular Surgery. (DOI:
10.1016/jvs.2009.05.023).
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doi:10.1016/j.ejvs.2009.05.017analysis of pooled data from ECST and NASCET (ESVS: A).4
There is equally strong consensus that CEA is inappropriate
for symptomatic patients with <50% stenosis (SVS: Grade 1/
High, ESVS: A). There is a general consensus as well on the
role of carotid artery stenting in symptomatic carotid
stenosis. Both the SVS and the ESVS documents support
consideration of carotid stenting (CAS) in ‘‘high risk’’
symptomatic patients, although the recommendation and
supporting data (SVS: Grade 2/Low, ESVS Grade C) are
much weaker than those supporting CEA. The ESVS adds
a recommendation that CEA is the preferred treatment in
symptomatic patients (Grade A) and that mid-term stroke
prevention with CEA and CAS are equivalent, based on mid-
term results of SPACE and EVA-3S (Grade A).5,6
In the recommendations for the management of asymp-
tomatic patients there are some subtle differences between
the SVS and ESVS documents. The threshold degree of
stenosis for intervention in asymptomatic patients in the SVS
document is 60%, based on ACAS, while in the ESVS document
it is 70%, based on ACST. The SVS and ESVS documents
recommend carotid endarterectomy for asymptomatic
patients with stenoses exceeding these threshold values
(SVS: Grade 1/High, ESVS: A). Recommendations in both
documents, however, include caveats: (SVS) ‘‘as long as
perioperative risk is low’’ and (ESVS) ‘‘males <75 if risk <3%
and younger, fit women’’. Based on the available RCT’s the
ESVS gender-related caveat seems appropriate, although
data of lower quality suggest no gender-related differences
in risk or stroke prevention benefit. The ESVS age related
caveat is more problematic as there are scant data sup-
porting an absolute age threshold over which benefit is lost.
The SVS and ESVS guidelines on the role of CAS in
asymptomatic patients reflect the considerable uncertainty
and controversy shrouding this area. The SVS document does
not support CAS for asymptomatic patients (Grade 1/Low).d by Elsevier Ltd. All rights reserved.
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244 C. Liapis et al.The ESVS supports CAS in asymptomatic patients only as part
of an RCT or in high volume centers with documented
excellent results (Grade C). In reality, as stated in their
discussion, the SVS authors could not reach consensus on
this recommendation which might more properly be Grade
II/low. The caveat added by the ESVS writing group is most
appropriate: ‘‘The assumption that a patient can be treated
with CAS when he has an (evidence based) indication for
CEA (carotid stenosis >50% in symptomatic or >70% in
asymptomatics) has not been validated.’’
The differences between the two documents are
primarily in their scope. The ESVS authors chose to include
much more detail on the techniques of CEA and CAS. In
general their technical recommendations for CEA are vague
and support surgeon preference (eversion vs longitudinal
technique, general vs regional anesthetic, cerebral moni-
toring and protection, and completion quality control
studies). It should be noted, however, that these vague
recommendations are based on meta-analyses from the
Cochrane Library, reflecting the best currently available
data. A more definitive recommendation is made for
carotid closure, where patch closure is recommended over
primary closure (Grade A). Also, routine shunting is not
supported (Grade A), but the origin of this recommendation
is unclear since the authors present no data suggesting that
routine shunting is inferior to selective shunting or non-
shunting. The SVS writing group felt that the quality of the
data and the likely strength of recommendations with
respect to the technical aspects of CEA and CAS were such
that inclusion of only brief technical notes was appropriate.
The SVS writing group espoused a broad range of technical
options, especially for CEA, and consensus was elusive.
The ESVS writing group also included a detailed analysis of
technique for carotid stenting. The only Grade A recom-
mendation to come from this analysis was for the use of dual
antiplatelet therapy (aspirin plus clopidogrel) for the
periprocedural period. Other technical recommendations
including the development of validated training programs,
the use of cerebral protection devices, and the duration of
dual antiplatelet therapy were given grade B or C. The SVS
writing group did not attempt a systematic review of the
evidence supporting technical aspects of CAS, though the
brief technical notes and recommendations from the SVS
group are nearly identical to those of the ESVS group.
Finally, the ESVS group evaluated evidence on the
management of concurrent carotid disease and peripheral
arterial disease (PAD) and on the management of concur-
rent carotid disease and coronary disease. Only Grade C
recommendations for not deferring PAD treatment in the
setting of asymptomatic carotid disease and for individu-
alizing the management of concurrent carotid and coronary
disease resulted.
Comparison of the SVS and ESVS carotid disease
management guidelines reveals transatlantic consensus
regarding the role of CEA in the management of symp-
tomatic and asymptomatic patients. This should not be
surprising, since the relevant data are both high quality and
explicit in their clinical application. Less clear and much
less explicit are the data supporting CAS, especially in
asymptomatic patients. It is not surprising, therefore, that
the emerging role of CAS is, as of now, much less clearly
defined in both North America and Europe.
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